Siteman Investment Program Research Development Awards (SIP RDAs)

The SIP RDA will fund research projects twice per year. Currently, there are eight mechanisms available:

  • CLINICAL TRIAL CATEGORY
    • New Clinical Trial Mechanism; up to $300,000 over 3 years
    • Existing Clinical Trial Mechanism; up to $200,000 over 2 years
    • Phase 0/1 Brain Tumor Center (BTC) Clinical Trial Mechanism; up to $75,000 over 3 years
  • PRE-R01 CATEGORY
    • The Pre-R01 Mechanism; up to $200,000 over 2 years
    • Pre-R01 Mechanism with a Cancer Prevention & Control Emphasis; up to $200,000 over 2 years
    • Pre-R01 Mechanism for University of Missouri-Columbia Collaboration; up to $200,000 over 2 years
  • TEAM SCIENCE CATEGORY
    • Team Science Mechanism; up to $800,000 over 2 years
  • COE SUPPLEMENT CATEGORY
    • COE Supplement Mechanism; up to $50,000 over 1 year (may request up to $100,000 directs with pre-approval as outlined in the RFA)

Complete information on each mechanism can be found in the Request for Applications (RFA) each cycle. A RFA will be announced twice per year on the following schedule:

GENERAL SIP DATE GUIDELINES* Cycle 1 Cycle 2
Announcement: January 15 July 15
Statement of Intent deadline: March 1 September 1
Full applications due: April 1 October 3
Anticipated decision notices: June 15 December 15
Start dates: July 1 January 1
*Dates may vary based on weekends, holidays, and other unforeseen circumstances.

Please consult the specific cycle’s RFA announcement for official deadlines.

2022 Cycle 2 Official Dates
Announcement: July 15, 2022
Statement of Intent Submission deadline: September 1, 2022
Application deadline: October 3, 2022
Anticipated decision notice: December 15, 2022
Start date: January 1, 2023

2022 Cycle 2 Application Documents

SIP RDA Request for Applications (RFA)
SIP RDA Application Cover Sheet Form (required – updated 07/2022)
SIP RDA Clinical Trial Category Budget Form (required – updated 07/2020)

Success Rates

Success rates have been computed over the span of SIP RDA by mechanism and include applications that were scientifically reviewed. Success rates are determined by dividing the number of applications funded by the total number of applications reviewed. The current success rate for the Pre-R01 Category is 21%.

Re-submissions are welcome and encouraged every cycle. The success rate for re-submissions across all mechanisms is 33%.

Previous Awardees

Contact Steve Baer at Siteman Cancer Center for more information, steve.baer@wustl.edu.